Hong Kong, China, September 21, 2026
Akeso, Inc. has announced that nearly 30 clinical studies from its innovative biopharmaceutical pipeline will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from October 23–27. A major highlight will be new overall survival data from the Phase 3 HARMONi-GI1 trial of ivonescimab in patients with advanced biliary tract cancer. The study has been selected as a Late-Breaking Abstract for the Presidential Symposium, with the results scheduled for an oral presentation during the congress. Ivonescimab, Akeso’s PD-1/VEGF bispecific antibody, will feature in 12 presentations covering multiple cancer types. The company will also present data from its second major bispecific antibody, cadonilimab, across 15 presentations involving more than 10 tumor types.
Ivonescimab Phase 3 Data Selected for ESMO
The HARMONi-GI1 Phase 3 study is evaluating ivonescimab combined with chemotherapy against durvalumab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer. Akeso said positive overall survival results from the randomized, controlled, double-blind study have been selected for the ESMO 2026 Late-Breaking Abstract program. The data will be presented during the Presidential Symposium on October 25, making the trial one of the company’s key clinical data disclosures at the meeting. Full results are expected to be released during the congress. Ivonescimab is being evaluated across a broad oncology development program. At ESMO 2026, additional presentations will cover its use in advanced renal cell carcinoma and recurrent or metastatic thymic carcinoma, including rapid oral presentations. Akeso is also continuing clinical development of ivonescimab in other difficult-to-treat malignancies, including lung cancer, gastrointestinal cancers, pancreatic cancer, glioblastoma, endometrial cancer, head and neck squamous cell carcinoma and thymic carcinoma. The breadth of these studies reflects the company’s strategy of evaluating the bispecific antibody across multiple tumor settings and treatment lines.
Cadonilimab Expands Bispecific Antibody Data
Akeso’s ESMO program will also feature extensive clinical data for cadonilimab, described by the company as a PD-1/CTLA-4 bispecific antibody. Fifteen presentations will cover more than ten cancer types, including gastric cancer, renal cell carcinoma, lung cancer, esophageal squamous cell carcinoma, colorectal cancer, nasopharyngeal carcinoma, ovarian cancer, soft tissue sarcoma, pleural mesothelioma and rectal cancer. The studies span different stages of treatment, including neoadjuvant therapy and first- and second-line treatment of advanced disease.
Advertisement
The ESMO presentations will provide an opportunity to examine clinical evidence across Akeso’s broader bispecific antibody portfolio. The company has developed an integrated research and development platform that includes its proprietary Tetrabody antibody technology, AI-powered drug R&D, Dual-Shield ADC, T-cell engager, tissue-targeted siRNA/mRNA and cell therapy platforms. Akeso reports that its pipeline contains more than 50 innovative assets, with nearly 30 candidates having entered clinical trials.
Akeso Highlights Broad Oncology Development Pipeline
The company’s ESMO 2026 presence comes as Akeso continues expanding its global immuno-oncology portfolio. Ivonescimab will be represented in 12 presentations, while cadonilimab will appear in 15, creating a substantial clinical data package across different tumor types. The company says the presentations reflect its ongoing efforts to advance next-generation immuno-oncology therapies for major diseases. For cGxP.wire readers, the most significant development is the upcoming disclosure of Phase 3 overall survival data for ivonescimab in first-line advanced biliary tract cancer. Although Akeso has described the results as positive, the detailed efficacy and safety findings have not yet been released in the announcement and are expected at ESMO. Therefore, the upcoming presentation will provide important additional information on the trial’s clinical outcomes and the potential role of PD-1/VEGF bispecific therapy in biliary tract cancer.
Source: Akeso press release
